



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|---|-------------------------------|
| Summary for ARTG Entry: | 233640 | METAGENICS GLUTATHIONE POWDER |
| ARTG entry for | Medicine Listed | |
| Sponsor | Metagenics (Aust) Pty Ltd | |
| Postal Address | PO Box 675, VIRGINIA BC, QLD, 4014 Australia | |
| ARTG Start Date | 11/02/2015 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS GLUTATHIONE POWDER

| | | | |
|---------------------|-------------------------|-----------------------|-----------|
| Product Type | Single Medicine Product | Effective Date | 1/07/2022 |
|---------------------|-------------------------|-----------------------|-----------|

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).
Not recommended for use by pregnant and lactating women (or words to that effect).
Adults only.

Additional Product information

Pack Size/Poison information

| | |
|------------------|------------------------|
| Pack Size | Poison Schedule |
|------------------|------------------------|

Components

1 . Formulation 1

| | |
|--------------------------------|--------------|
| Dosage Form | Powder, oral |
| Route of Administration | Oral |

Visual Identification

Active Ingredients

| | |
|-------------|----------|
| glutathione | 200 mg/g |
|-------------|----------|

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Other Ingredients (Excipients)

Flavour

maltodextrin

silicon dioxide

Steviol glycosides

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary